Literature DB >> 18588934

The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers.

Jeffrey S Kennedy1, Mary Co, Sharone Green, Karen Longtine, Jaclyn Longtine, Melissa A O'Neill, Janice P Adams, Alan L Rothman, Qiao Yu, Renita Johnson-Leva, Ranajit Pal, Shixia Wang, Shan Lu, Phillip Markham.   

Abstract

This report describes the safety observations following administration of a polyvalent DNA prime-protein boost HIV-1 vaccine formulated with adjuvant QS21. Local injection site reactions were the most common (65% of subjects), and included type IV delayed-type hypersensitivity (DTH) reactions at prior DNA inoculation sites in 12 of 28 (43%) subjects following protein vaccination. Systemic reactions revealed two cases of vasculitis temporally related to inoculation with recombinant Env protein+QS21 adjuvant. Questions remain regarding the cause of the vasculitis, but the unique DTH observation may have contributed to the high level of immune responses previously reported for this vaccine.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18588934      PMCID： PMC2571083          DOI： 10.1016/j.vaccine.2008.05.090

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  35 in total

1.  Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers.

Authors:  G Pialoux; H Gahéry-Ségard; S Sermet; H Poncelet; S Fournier; L Gérard; A Tartar; H Gras-Masse; J P Levy; J G Guillet
Journal:  AIDS       Date:  2001-07-06       Impact factor: 4.177

Review 2.  New hope for an AIDS vaccine.

Authors:  Harriet L Robinson
Journal:  Nat Rev Immunol       Date:  2002-04       Impact factor: 53.106

3.  Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization.

Authors:  J-M Orgogozo; S Gilman; J-F Dartigues; B Laurent; M Puel; L C Kirby; P Jouanny; B Dubois; L Eisner; S Flitman; B F Michel; M Boada; A Frank; C Hock
Journal:  Neurology       Date:  2003-07-08       Impact factor: 9.910

4.  QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.

Authors:  T G Evans; M J McElrath; T Matthews; D Montefiori; K Weinhold; M Wolff; M C Keefer; E G Kallas; L Corey; G J Gorse; R Belshe; B S Graham; P W Spearman; D Schwartz; M J Mulligan; P Goepfert; P Fast; P Berman; M Powell; D Francis
Journal:  Vaccine       Date:  2001-02-28       Impact factor: 3.641

5.  Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines.

Authors:  J D Boyer; A D Cohen; S Vogt; K Schumann; B Nath; L Ahn; K Lacy; M L Bagarazzi; T J Higgins; Y Baine; R B Ciccarelli; R S Ginsberg; R R MacGregor; D B Weiner
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

6.  Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid.

Authors:  David H Cribbs; Anahit Ghochikyan; Vitaly Vasilevko; Mike Tran; Irina Petrushina; Nadya Sadzikava; Davit Babikyan; Patrick Kesslak; Thomas Kieber-Emmons; Carl W Cotman; Michael G Agadjanyan
Journal:  Int Immunol       Date:  2003-04       Impact factor: 4.823

7.  Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites.

Authors:  James G Kublin; Mark H Lowitt; Robert G Hamilton; Giane A Oliveira; Elizabeth H Nardin; Ruth S Nussenzweig; Barbara J Schmeckpeper; Carter L Diggs; Sacared A Bodison; Robert Edelman
Journal:  Vaccine       Date:  2002-03-15       Impact factor: 3.641

8.  Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data.

Authors:  R R MacGregor; J D Boyer; R B Ciccarelli; R S Ginsberg; D B Weiner
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

9.  Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized.

Authors:  Hanne Gahéry-Ségard; Gilles Pialoux; Suzanne Figueiredo; Céline Igéa; Mathieu Surenaud; Jessintha Gaston; Helene Gras-Masse; Jean-Paul Lévy; Jean-Gérard Guillet
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers.

Authors:  Shixia Wang; Jeffrey S Kennedy; Kim West; David C Montefiori; Scott Coley; John Lawrence; Siyuan Shen; Sharone Green; Alan L Rothman; Francis A Ennis; James Arthos; Ranajit Pal; Phillip Markham; Shan Lu
Journal:  Vaccine       Date:  2008-01-10       Impact factor: 3.641
View more
  32 in total

1.  Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001.

Authors:  Matthew R Costa; Justin Pollara; Regina Whitney Edwards; Michael S Seaman; Miroslaw K Gorny; David C Montefiori; Hua-Xin Liao; Guido Ferrari; Shan Lu; Shixia Wang
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

2.  Characterization of T-cell responses in macaques immunized with a single dose of HIV DNA vaccine.

Authors:  Géraldine Arrode-Brusés; Darlene Sheffer; Ramakrishna Hegde; Sukbir Dhillon; Zhengian Liu; François Villinger; Opendra Narayan; Yahia Chebloune
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

3.  Synthesis of the hexacyclic triterpene core of the jujuboside saponins via tandem Wolff rearrangement-intramolecular ketene hetero-Diels-Alder reaction.

Authors:  Rashad R Karimov; Derek S Tan; David Y Gin
Journal:  Tetrahedron       Date:  2018-04-19       Impact factor: 2.457

4.  Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine.

Authors:  Jian Yan; Daniel O Villarreal; Trina Racine; Jaemi S Chu; Jewell N Walters; Matthew P Morrow; Amir S Khan; Niranjan Y Sardesai; J Joseph Kim; Gary P Kobinger; David B Weiner
Journal:  Vaccine       Date:  2014-03-12       Impact factor: 3.641

5.  Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer.

Authors:  Joseph P Nkolola; Christine A Bricault; Ann Cheung; Jennifer Shields; James Perry; James M Kovacs; Elena Giorgi; Margot van Winsen; Adrian Apetri; Els C M Brinkman-van der Linden; Bing Chen; Bette Korber; Michael S Seaman; Dan H Barouch
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

6.  Identification of Aim2 as a sensor for DNA vaccines.

Authors:  John J Suschak; Shixia Wang; Katherine A Fitzgerald; Shan Lu
Journal:  J Immunol       Date:  2014-12-08       Impact factor: 5.422

7.  Design and synthesis of potent Quillaja saponin vaccine adjuvants.

Authors:  Michelle M Adams; Payal Damani; Nicholas R Perl; Annie Won; Feng Hong; Philip O Livingston; Govind Ragupathi; David Y Gin
Journal:  J Am Chem Soc       Date:  2010-02-17       Impact factor: 15.419

Review 8.  Technical transformation of biodefense vaccines.

Authors:  Shan Lu; Shixia Wang
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

Review 9.  Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).

Authors:  Michael Vaine; Shan Lu; Shixia Wang
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

10.  Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen.

Authors:  Ekaterina Alekseeva; Irina Sominskaya; Dace Skrastina; Irina Egorova; Elizaveta Starodubova; Eriks Kushners; Marija Mihailova; Natalia Petrakova; Ruta Bruvere; Tatyana Kozlovskaya; Maria Isaguliants; Paul Pumpens
Journal:  Genet Vaccines Ther       Date:  2009-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.